title: Potential role for metformin in urologic oncology.
abstract: Metformin is one of the most commonly used drugs worldwide. It is currently considered first-line pharmacological agent for management of diabetes mellitus type 2. Recent studies have suggested that metformin may have further benefits, especially in the field of urologic oncology. Use of metformin has been shown to be associated with decreased incidence and improved outcomes of prostate, bladder, and kidney cancer. These studies suggest that metformin does have a future role in the prevention and management of urologic malignancies. In this review, we will discuss the latest findings in this field and its implications on the management of urologic oncology patients.
authors.affiliation: Department of Urology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
authors.forename: Rashid Khalid
authors.initials: RK
authors.lastname: Sayyid
authors.affiliation: Department of Urology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
authors.forename: Neil Eric
authors.initials: NE
authors.lastname: Fleshner
mesh_terms: D016588:Anticarcinogenic Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000628:therapy; D006801:Humans; D007680:Kidney Neoplasms / Q000628:therapy; D008297:Male; D008687:Metformin / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000628:therapy; D001749:Urinary Bladder Neoplasms / Q000628:therapy; D014571:Urologic Neoplasms / Q000628:therapy*
chemical_list: D016588:Anticarcinogenic Agents; D000970:Antineoplastic Agents; D008687:Metformin
keywords: Kidney neoplasms; Metformin; Prostatic neoplasms; Urinary bladder neoplasms